SpringWorks Therapeutics (SWTX)
(Real Time Quote from BATS)
$36.14 USD
-0.07 (-0.19%)
Updated Aug 16, 2024 12:14 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Brokerage Reports
SpringWorks Therapeutics [SWTX]
Reports for Purchase
Showing records 61 - 80 ( 195 total )
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
3Q22 Financials Reported; Modulating PT to $99, Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Niro Springing Forward Towards Data and Potential Launch
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Biotechnology- EORTC-NCI-AACR 2022: Covered Companies Roundup
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Relevant Abstracts at Upcoming EORTC-NCI-AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Competitor KOL Event Pays Homage to Emperor Niro
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
First Ovarian Granulosa Cell Tumor Patient Dosed With Nirogacestat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Nirogacestat is New Standard-of-Care for Desmoid Tumors; RAFi Competitive Landscape Updates; Modulating PT to $103
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Niro Breaking the Competition in Desmoid Tumors
Provider: Wedbush Securities Inc.
Analyst: Research Department
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
ESMO 2022 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: SpringWorks Therapeutics
Industry: Medical - Biomedical and Genetics
Awaiting Clarity for Nirogacestat + BCMA-Targeted Agents; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R